Company
Headquarters: Liuyang, China
Employees: 1,651
CEO: Mr. Fangwen Shuai
CN¥4.56 Billion
CNY as of July 1, 2024
US$626.9 Million
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Hunan Er-Kang Pharmaceutical Co., Ltd manufactures and sells APIs, finished drug products, and pharmaceutical excipients in China and internationally. Its APIs include glycerin, dilute hydrochloric acid, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. The company's finished drugs primarily comprise sulbenicillin sodium for injection and compound liquorice tablets. Its conventional pharmaceutical excipients include pharmaceutical glycerin, medicinal ethanol, medicinal propylene glycol, medicinal sodium hydroxide, and sucrose; and new pharmaceutical excipients comprise hydroxypropyl starch empty capsules, hydroxypropyl starch soft capsules, and citrate and its series products. The company was founded in 2003 and is based in Liuyang, China.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Hunan Er-Kang Pharmaceutical Co. Ltd has the following listings and related stock indices.
Stock: SZSE: 300267 wb_incandescent